Merck & Co., Inc. (NYSE:MRK) is among the 15 Best Stocks to Buy for Medium Term. BofA analyst raised the price target on MRK to $105, maintaining a Buy rating. MRK reported third-quarter revenue of $17.3 billion, with KEYTRUDA sales growing 10% to $8.1 billion. The company expects revenue to reach $64.5-65 billion.

Merck & Co., Inc. (NYSE:MRK) has made progress with new approvals like Winreva‍ir and Capvaxive, generating millions in sales. The company also saw growth in its animal health business, with sales rising 9%. MRK provides healthcare solutions through prescription medicines, vaccines, and more.

While MRK presents investment potential, certain AI stocks offer greater upside. Explore an undervalued AI stock with significant potential. For long-term investment options, check out the 15 Best Long Term Stocks to Buy According to Reddit and 13 Best Canadian Dividend Stocks to Buy and Hold.

Read more at Yahoo Finance: BofA Raises Merck (MRK) Price Target to $105, Keeps Buy Rating